Nosocomial infection caused by Carbapenem-Resistant Acinetobacter baumannii (CR-A. baumannii) has become a challenge in clinical practice. Acting as the last resort antibacterial agents for the treatment of CR-A. baumannii infection, polymyxins have high risk of nephrotoxicity and poor clinical efficacy. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam are three β-lactam/β-lactamase inhibitor combination complexes that newly approved by the Food and Drug Administration for the treatment of carbapenem-resistant Gram-negative bacterial infection. In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A. baumannii obtained from a Chinese tertiary hospital. Our results suggest that those novel antibacterial agents should not be used alone for the treatment of CR-A. baumannii infection, as they cannot prevent the regrowth of bacteria at the clinical achievable blood concentration. Imipenem/relebactam and meropenem/vaborbactam should not be used as the substitutes of imipenem and meropenem for polymyxin B based combination therapy against CR-A. baumannii, since they have no edge over imipenem and meropenem on antibacterial activity when in combination with polymyxin B. Ceftazidime/avibactam may be more suitable than ceftazidime for polymyxin B based combination therapy against CR-A. baumannii, as it has a higher synergistic rate with polymyxin B, and the antibacterial activity of ceftazidime/avibactam is much higher than that of ceftazidime when tested in combination with polymyxin B. Ceftazidime/avibactam may also be the better choice than imipenem and meropenem for polymyxin B based combination therapy against CR-A. baumannii, as it has a higher synergistic rate with polymyxin B.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315–33.
Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics (Basel). 2020;9:205.
Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48:6987–98.
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019[M]. US Department of Health and Human Services, Centres for Disease Control and Prevention, 2019.
Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X, et al. China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:2275–81.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis. 2020;71:e523–e529.
Wang Y, Ma X, Zhao L, He Y, Yu W, Fu S, et al. Heteroresistance is associated with in vitro regrowth during colistin treatment in carbapenem-resistant Klebsiella pneumoniae. Front Microbiol. 2022;13:868991.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004;54:566–9.
Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.
Lenhard JR, Nation RL, Tsuji BT. Synergistic combinations of polymyxins. Int J Antimicrob Agents. 2016;48:607–13.
Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An update on eight “new” antibiotics against multidrug-resistant gram-negative bacteria. J Clin Med. 2021;10:1068.
Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78:65–98.
El Hafi B, Rasheed SS, Abou Fayad AG, Araj GF, Matar GM. Evaluating the efficacies of carbapenem/β-lactamase inhibitors against carbapenem-resistant gram-negative bacteria in vitro and in vivo. Front Microbiol. 2019;10:933.
Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, et al. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother. 2021;76:2071–8.
Zhang H, Jia P, Zhu Y, Zhang G, Zhang J, Kang W, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509–18.
Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.
Shah PJ, Tran T, Emelogu F, Tariq F. Aztreonam, Ceftazidime/Avibactam, and colistin combination for the management of carbapenemase-producing Klebsiella pneumoniae bacteremia: a case report. J Pharm Pract. 2021;34:653–7.
Khorsi K, Messai Y, Hamidi M, Ammari H, Bakour R. High prevalence of multidrug-resistance in Acinetobacter baumannii and dissemination of carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like and blaNDM-1 in Algiers hospitals. Asian Pac J Trop Med. 2015;8:438–46.
Bertini A, Poirel L, Bernabeu S, Fortini D, Villa L, Nordmann P, et al. Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:2324–8.
Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991;276:269–70.
Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–58.
Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18:263–72.
Kuiper SG, Leegwater E, Wilms EB, van Nieuwkoop C. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections. Expert Opin Pharmacother. 2020;21:1805–11.
Groft LM, Claeys KC, Heil EL. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. Expert Opin Pharmacother. 2021;22:265–71.
Savov E, Trifonova A, Kovachka K, Kjosseva E, Strateva T. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa - a pilot Bulgarian study. Infect Dis (Lond). 2019;51:870–3.
Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e01443–17.
Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Micro Genom. 2019;5:e000306.
Yu H, Ezpeleta-Lobato G, Han X, Carmona-Cartaya Y, Quiñones-Pérez D. Carbapenamase-producing Acinetobacter baumannii in China, Latin America and the Caribbean. MEDICC Rev. 2022;24:59–69.
Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2010;54:24–38.
Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.
Fomnya HJ, Ngulde SI, Amshi KA, Bilbonga G. Antibiotics: classifications and mechanism of resistance[J]. Appl Microbiol Biotechnol. 2021;9:38–50.
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55.
Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:2720–5.
Olsson A, Wistrand-Yuen P, Nielsen EI, Friberg LE, Sandegren L, Lagerbäck P, et al. Efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments. Antimicrob Agents Chemother. 2020;64:e02111–19.
Wickremasinghe H, Yu HH, Azad MAK, Zhao J, Bergen PJ, Velkov T, et al. Clinically relevant concentrations of polymyxin B and meropenem synergistically kill multidrug-resistant Pseudomonas aeruginosa and minimize biofilm formation. Antibiotics (Basel). 2021;10:405.
Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, et al. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist. 2019;18:37–44.
Xie J, Roberts JA, Lipman J, Cai Y, Wang H, Zhao N, et al. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Int J Antimicrob Agents. 2020;55:105943.
Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. Role of renal drug exposure in polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother. 2017;61:e02391–16.
The authors are grateful to the Shiyan Renmin Hospital of Hubei University of Medicine and the Ningbo Yinzhou No.2 Hospital of Ningbo University. This work was supported by Shiyan Science and Technology Bureau (Grant No: 20Y46).
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liang, R., Wang, D., Hu, M. et al. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii. J Antibiot (2023). https://doi.org/10.1038/s41429-023-00631-0